Member Info for schlemiel

Gas hopeful Tamboran pitches Trump on $8b outback data centre plan

Washington |

Tamboran Resources, the ASX-listed gas developer which is backed by a company chaired by the incoming US energy secretary, has asked the Trump administration to invest $US5 billion ($8 billion) in a data centre project to be used for defence and at operations such as Pine Gap.

Tamboran chief executive Joel Riddle flew to Washington this week to meet with the administration, government agencies and data centre investors and pitch the secret proposal for a data centre.

https://www.afr.com/world/north-america/gas-hopeful-tamboran-pitches-trump-on-8b-outback-data-centre-plan-20250123-p5l6l0

'New article in the AFR, riddle across in the US pitching an idea to build an outback data center powered by beetaloo gas'

'A Memorandum of Understanding was executed with Tamboran Resources to complete a joint study on gas export options for Beetaloo through DLNG expansion up to approved nominal 10 Mtpa capacity.'

https://company-announcements.afr.com/asx/sto/1b55fab1-d912-11ef-b615-7a07d4dd6f05.pdf

Tamboran and Santos execute MOU to progress studies for Darwin LNG expansion

Highlights

Tamboran Resources Corporation and Santos Limited (ASX: STO) have entered into a non-binding Memorandum of Understanding (MOU) to undertake technical studies relating to a potential Darwin LNG (DLNG) Train 2 expansion and collaborative work on the jointly owned EP 161 acreage (Santos 75% operator, Tamboran 25%) in the Beetaloo Basin.

The goal of the studies is to evaluate options for supplying natural gas to a potential expansion train at the existing DLNG facility at Middle Arm. DLNG was approved to a nominal 10 million tonnes of LNG per annum (MTPA), with this expansion opportunity up to ~6 MTPA.

Santos is the operator of the existing DLNG project with a 43.4% working interest.

Tamboran and Santos are joint venture partners in the EP 161 acreage which holds ~300,000 acres of Mid Velkerri B Shale at depths below 8,850 feet (~2,700 metres). The region has demonstrated Marcellus Basin-type decline curves from two Tanumbirini wells that were drilled and flow tested in 2022.

Tamboran remains committed to progressing the development of the proposed NTLNG project at Middle Arm, which is currently undergoing pre-FEED studies with Bechtel Corporation.

Tamboran and Santos are both committed to supplying natural gas from the Beetaloo Basin into both the Australian domestic gas and international LNG markets.

Look at the volume. Off the scale day

thanks to those excellent researchers

Go on GGP. Great day for all concerned.

Well done to all

It's all about COMMERCIAL flow rates now

Will this be seen as good? Hopefully

Nm

Near Neighbour Activities

'The Company is closely monitoring neighbouring leaseholder, Pantheon Resources PLC (Pantheon), following the successful spud of its Megrez-1 well in December 2024, ahead of an extended well test scheduled for Q1 CY25. Pantheon is targeting the Ahpun Eastern Topset reservoir. This test is a crucial step towards confirming the commercial viability and development potential of this reservoir. If successful, it would enhance the understanding of its production potential, further supporting the regional development potential and commercialisation pathways, which will positively impact on the Company’s plans to commercialise Project Phoenix.'

https://clients3.weblink.com.au/pdf/88E/02904668.pdf

NM

No stopping this at present. News due, obviously?

Nm

What the feck is going on 'ere? Up, up and up. surely something substantive in the pipeline

Moving

'Outlook

'Whilst continuing to be mindful of the timing of pipeline conversion due to potential disruption in elements of the automotive market and customer delivery schedules, the Board remains confident that the Group will make further financial and strategic progress this year, and its expectations for FY 2025 are unchanged. Future growth prospects remain supported by long-term structural and regulatory growth drivers in active safety, autonomous systems and the automation of vehicle applications.'

1 Reduction in the sum of longest diameters (SLD) is used to measure response per RECIST 1.1 with partial responses having at least a 30% reduction and minor responses of between >10% and

1 Reduction in the sum of longest diameters (SLD) is used to measure response per RECIST 1.1 with partial responses having at least a 30% reduction and minor responses of between >10% and

Clinical data observations:

Out of 10 patients with SGC treated at the dose of 250 mg/m2 and above, 5 patients experienced clinically meaningful disease shrinkage, including a confirmed partial response (PR, 45% tumor shrinkage) and four minor responses (MR, 10-19.5% tumor shrinkage) using RECIST criteria.1 These data include the following cases:

· A durable, confirmed PR was observed at 12 weeks in a 79-year-old male patient. The response is ongoing despite patient discontinuation due to reaching lifetime maximum of doxorubicin exposure. This patient began their treatment with AVA6000 in October 2023 following one line of therapy which he experienced disease progression prior to enrolling in the AVA6000 clinical trial.

· Rapid and complete regression of large skin and visceral metastasis was observed in a 74-year-old male patient experiencing a MR, despite low to mid-level FAP expression in the cancer-associated fibroblasts alone. A 15% reduction in parotid and lymph nodal lesions continues at the12 weeks post scan. This patient began treatment in September 2024 following two prior lines of therapy to which he experienced disease progression with both therapies prior to enrolling in the AVA6000 trial.

Although these data are reported early in the treatment course of most patients, it is notable that six patients (of the 10 patients with SGC), including all five responders, remain on treatment and a further two patients remain in progression-free follow-up after having received the maximum number of cycles of AVA6000. Only one patient has reported disease progression as best response resulting in the disease control rate of 90% in this group of patients with salivary gland cancers.

Treatment with AVA6000 continues to be well-tolerated in both dosing arms, once every two weeks (Q2W) and once every three weeks (Q3W), with reduced hematologic and cardiac toxicities compared to conventional dose doxorubicin at 75 mg/m2 dosed every 3 weeks. A maximum tolerated dose has not been identified in either arm of the trial.

1 Reduction in the sum of longest diameters (SLD) is used to measure response per RECIST 1.1 with partial responses having at least a 30% reduction and minor responses of between >10% and

Christina Coughlin MD, PhD, CEO of Avacta, commented,

"These data highlight the transformative potential of our pre|CISION® peptide drug conjugates in expanding the efficacy of highly potent therapeutics and support our growing optimism in this program.

"Salivary gland cancer is a devastating disease with no established standard of care treatment options. AVA6000 demonstrated a clinically meaningful tumor shrinkage in SGC patients, highlighting its potential as an important new treatment option for patients with SGC and other solid tumors.

"We look forward to continuing to work with our investigators and the broader community to explore its potential in SGC and other cancers. We are thrilled to begin enrollment in the expansion cohorts, and this part of the trial will also be conducted in less heavily pretreated patients which will allow us to better understand the potential of AVA6000 in these disease settings with high unmet need."

These results demonstrate preliminary evidence of durable antitumor activity in patients with SGC, supported by ongoing RECIST1 responses (both partial and minor responses) in a disease setting with no standard of care. SGC accounts for 6-8% of head and neck cancers in the US, with approximately 2,500 cases diagnosed in the US each year2. There is no standard of care for SGC once patients have developed distant metastasis, with a five year survival rate of approximately 43%.